Literature DB >> 9497857

Gaucher's disease: clinical features and natural history.

T M Cox1, J P Schofield.   

Abstract

Gaucher's disease is an inherited disorder characterized by pathological storage of glycolipid in mononuclear phagocytes: it is a multi-system disease associated with striking variation in its clinical manifestations, severity and course. Although molecular analysis of the glucocerebrosidase gene in patients with Gaucher's disease has permitted broad correlations between genotype and phenotype to be made, with few exceptions genetic variation at this locus does not allow confident prediction of clinical phenotype or prognosis. Partial deficiency of glucocerebrosidase is associated principally with parenchymal disease of the liver, spleen, bone marrow and, in severe cases, the lung, in non-neuronopathic, Type 1, Gaucher's disease: here storage material in macrophages originates from turnover of exogenous glycolipids. Severe deficiency of glucocerebrosidase caused by disabling mutations is additionally associated with neurological manifestations that in part reflect a failure to degrade endogenous neuronal glycosphingolipids, the so-called neuronopathic, Type 2 and Type 3 disease categories. Here we describe the clinical features, complications and natural history principally of Type 1 Gaucher's disease: emphasis is placed on emerging pulmonary, osseous and other manifestations of obscure pathogenesis that respond poorly to enzyme-replacement therapy.

Entities:  

Mesh:

Year:  1997        PMID: 9497857     DOI: 10.1016/s0950-3536(97)80033-9

Source DB:  PubMed          Journal:  Baillieres Clin Haematol        ISSN: 0950-3536


  60 in total

Review 1.  Radiological aspects of Gaucher disease.

Authors:  Robert Katz; Tom Booth; Rikin Hargunani; Peter Wylie; Brian Holloway
Journal:  Skeletal Radiol       Date:  2010-07-25       Impact factor: 2.199

2.  Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype.

Authors:  Sarah M Lo; Philip Stein; Sean Mullaly; Michael Bar; Dhanpat Jain; Gregory M Pastores; Pramod K Mistry
Journal:  Am J Hematol       Date:  2010-05       Impact factor: 10.047

Review 3.  Revised recommendations for the management of Gaucher disease in children.

Authors:  Paige Kaplan; Hagit Baris; Linda De Meirleir; Maja Di Rocco; Amal El-Beshlawy; Martina Huemer; Ana Maria Martins; Ioana Nascu; Marianne Rohrbach; Lynne Steinbach; Ian J Cohen
Journal:  Eur J Pediatr       Date:  2012-07-08       Impact factor: 3.183

4.  Recombinant human acid beta-glucosidase stored in tobacco seed is stable, active and taken up by human fibroblasts.

Authors:  Serena Reggi; Stefano Marchetti; Tamara Patti; Francesca De Amicis; Roberta Cariati; Bruno Bembi; Corrado Fogher
Journal:  Plant Mol Biol       Date:  2005-01       Impact factor: 4.076

5.  [Pathology along the liver sinusoids: intrasinusoidal findings].

Authors:  U Flucke; H-P Fischer
Journal:  Pathologe       Date:  2008-02       Impact factor: 1.011

6.  Neurochemical abnormalities in patients with type 1 Gaucher disease on standard of care therapy.

Authors:  Reena V Kartha; James Joers; Marcia R Terluk; Abigail Travis; Kyle Rudser; Paul J Tuite; Neal J Weinreb; Jeanine R Jarnes; James C Cloyd; Gülin Öz
Journal:  J Inherit Metab Dis       Date:  2019-12-17       Impact factor: 4.982

Review 7.  Clinically relevant therapeutic endpoints in type I Gaucher disease.

Authors:  C E Hollak; M Maas; J M Aerts
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

8.  GAUCHER'S DISEASE.

Authors:  C Vidyashankar; R K Sharma; S S Bhatia; S C Sharma; D Ranganathan
Journal:  Med J Armed Forces India       Date:  2017-06-26

9.  Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease.

Authors:  Juliane Neumann; Jose Bras; Emma Deas; Sean S O'Sullivan; Laura Parkkinen; Robin H Lachmann; Abi Li; Janice Holton; Rita Guerreiro; Reema Paudel; Badmavady Segarane; Andrew Singleton; Andrew Lees; John Hardy; Henry Houlden; Tamas Revesz; Nicholas W Wood
Journal:  Brain       Date:  2009-03-13       Impact factor: 13.501

10.  Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.

Authors:  Pramod K Mistry; Patrick Deegan; Ashok Vellodi; J Alexander Cole; Michael Yeh; Neal J Weinreb
Journal:  Br J Haematol       Date:  2009-09-03       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.